Article Versions Notes

Li Y, Mueller LI, Neuhaus JP, Bertram S, Schaarschmidt BM, Demircioglu A, Ludwig JM, Kirchner J, Rischpler C, Herrmann K, et al. ¹⁸F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET? Journal of Clinical Medicine. 2020; 9(10):3163. https://doi.org/10.3390/jcm9103163

Li, Yan, Laura Isabel Mueller, Jan Peter Neuhaus, Stefanie Bertram, Benedikt Michael Schaarschmidt, Aydin Demircioglu, Johannes Maximilian Ludwig, Julian Kirchner, Christoph Rischpler, Ken Herrmann, and et al. 2020. "¹⁸F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET?" Journal of Clinical Medicine 9, no. 10: 3163. https://doi.org/10.3390/jcm9103163

Li, Y., Mueller, L. I., Neuhaus, J. P., Bertram, S., Schaarschmidt, B. M., Demircioglu, A., Ludwig, J. M., Kirchner, J., Rischpler, C., Herrmann, K., Catalano, O. A., & Umutlu, L. (2020). ¹⁸F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET? Journal of Clinical Medicine, 9(10), 3163. https://doi.org/10.3390/jcm9103163